Tags

Type your tag names separated by a space and hit enter

Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation.
Acta Neurol Belg. 1998 Dec; 98(4):332-41.AN

Abstract

Cost-effectiveness and cost per successful treatment has been evaluated in 186 outpatients randomised to treat moderate to severe migraine attacks either with subcutaneous sumatriptan 6 mg (n = 97) or with their current therapy (n = 89) during an open, multicentre study of 3 months. Within 2 hours, headache severity decreased to none/mild in 86% of all attacks in the sumatriptan group (STG) compared to 25% in the customary group (CTG). Migraine was alleviated earlier in the STG than in the CTG (median 3.78 vs. 13.39 hours, p < 0.0001). The direct and total cost of treatment was 133 and 2012 BF, respectively, in the CTG and 1400 and 2522 BF, respectively, in the STG. Measuring the effectiveness of earlier pain relief with sumatriptan, the incremental cost-effective ratios for direct and total cost were 132 and 53 BF per hour of relieved pain, respectively. For this price, significantly more sumatriptan patients improved their quality of life by more than 20% (61.6 vs. 20.6% patients, p < 0.001) and less sumatriptan patient consulted a medical professional (11.3 vs. 29.2% patients, p < 0.01), used less medication for adverse events (6.2 vs. 22.5%, p < 0.001) and suffered less from associated migraine symptoms. The median number of hours of diminished work-efficiency (3 vs. 7 hours, p < 0.01) or of suspension of non-professional activity (10 vs. 24 hours, p < 0.001) was also significantly lower in the STG. The total cost per successfully treated patient was lower in the STG. Sumatriptan is more effective, provides a better quality of life, reduces health care resource utilisation, and improves work productivity as compared to the CTG, thereby resulting in a favourable cost-effectiveness ratio.

Authors+Show Affiliations

Laloux P
Department of Neurology, Mont-Godinne University Hospital, Louvain Medical School, Yvoir, Belgium.
Vakaet A
No affiliation info available
Monseu G
No affiliation info available
Jacquy J
No affiliation info available
Bourgeois P
No affiliation info available
van der Linden C
No affiliation info available

MeSH

AbsenteeismAdolescentAdultAnalgesicsCost-Benefit AnalysisDrug CostsFemaleHumansInjections, SubcutaneousMaleMiddle AgedMigraine DisordersPatient Acceptance of Health CareQuality of LifeSafetySerotonin Receptor AgonistsSumatriptanVasoconstrictor Agents

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9922821

Citation

Laloux, P, et al. "Subcutaneous Sumatriptan Compared With Usual Acute Treatments for Migraine: Clinical and Pharmacoeconomic Evaluation." Acta Neurologica Belgica, vol. 98, no. 4, 1998, pp. 332-41.
Laloux P, Vakaet A, Monseu G, et al. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation. Acta Neurol Belg. 1998;98(4):332-41.
Laloux, P., Vakaet, A., Monseu, G., Jacquy, J., Bourgeois, P., & van der Linden, C. (1998). Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation. Acta Neurologica Belgica, 98(4), 332-41.
Laloux P, et al. Subcutaneous Sumatriptan Compared With Usual Acute Treatments for Migraine: Clinical and Pharmacoeconomic Evaluation. Acta Neurol Belg. 1998;98(4):332-41. PubMed PMID: 9922821.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation. AU - Laloux,P, AU - Vakaet,A, AU - Monseu,G, AU - Jacquy,J, AU - Bourgeois,P, AU - van der Linden,C, PY - 1999/1/29/pubmed PY - 1999/1/29/medline PY - 1999/1/29/entrez SP - 332 EP - 41 JF - Acta neurologica Belgica JO - Acta Neurol Belg VL - 98 IS - 4 N2 - Cost-effectiveness and cost per successful treatment has been evaluated in 186 outpatients randomised to treat moderate to severe migraine attacks either with subcutaneous sumatriptan 6 mg (n = 97) or with their current therapy (n = 89) during an open, multicentre study of 3 months. Within 2 hours, headache severity decreased to none/mild in 86% of all attacks in the sumatriptan group (STG) compared to 25% in the customary group (CTG). Migraine was alleviated earlier in the STG than in the CTG (median 3.78 vs. 13.39 hours, p < 0.0001). The direct and total cost of treatment was 133 and 2012 BF, respectively, in the CTG and 1400 and 2522 BF, respectively, in the STG. Measuring the effectiveness of earlier pain relief with sumatriptan, the incremental cost-effective ratios for direct and total cost were 132 and 53 BF per hour of relieved pain, respectively. For this price, significantly more sumatriptan patients improved their quality of life by more than 20% (61.6 vs. 20.6% patients, p < 0.001) and less sumatriptan patient consulted a medical professional (11.3 vs. 29.2% patients, p < 0.01), used less medication for adverse events (6.2 vs. 22.5%, p < 0.001) and suffered less from associated migraine symptoms. The median number of hours of diminished work-efficiency (3 vs. 7 hours, p < 0.01) or of suspension of non-professional activity (10 vs. 24 hours, p < 0.001) was also significantly lower in the STG. The total cost per successfully treated patient was lower in the STG. Sumatriptan is more effective, provides a better quality of life, reduces health care resource utilisation, and improves work productivity as compared to the CTG, thereby resulting in a favourable cost-effectiveness ratio. SN - 0300-9009 UR - https://www.unboundmedicine.com/medline/citation/9922821/Subcutaneous_sumatriptan_compared_with_usual_acute_treatments_for_migraine:_clinical_and_pharmacoeconomic_evaluation_ L2 - http://www.diseaseinfosearch.org/result/4811 DB - PRIME DP - Unbound Medicine ER -